| Trial ID: | L5877 |
| Source ID: | NCT01698931
|
| Associated Drug: |
Repaglinide
|
| Title: |
Efficacy of Repaglinide in Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: repaglinide|DRUG: glyburide|DRUG: placebo
|
| Outcome Measures: |
Primary: Basal hepatic glucose production, Day 0; day 44 | Secondary: Number of hypoglycaemic episodes, Day 0; day 44|Change in body weight, Day 0; day 44|Number of adverse events, Day 0; day 44
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
9
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2002-04-26
|
| Completion Date: |
2003-03-06
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-20
|
| Locations: |
Novo Nordisk Investigational Site, Padova, 35137, Italy
|
| URL: |
https://clinicaltrials.gov/show/NCT01698931
|
